Research programme: neurobehavioural disorders therapeutics - BlackThorn Therapeutics

Alternative Names: BTRX Program 2; BTRX Program 3; BTRX Program 4; BTRX-335140; BTRX-395750

Latest Information Update: 17 Apr 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator BlackThorn Therapeutics
Class Neuroprotectants; Small molecules
Mechanism of Action Opioid kappa receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Neurological disorders

Most Recent Events

06 Apr 2017 Pharmacodynamics data from a preclinical trial in Neurological disorders released by BlackThorn Therapeutics
20 Oct 2016 Preclinical trials in Neurological disorders in USA (unspecified route) (BlackThorn Therapeutics pipeline, October 2016)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.